iOmx Therapeutics Initiates Phase Ib with OMX-0407


MARTINSRIED, Germany and MUNICH, Aug. 22, 2024 (GLOBE NEWSWIRE) -- iOmx Therapeutics AG (iOmx), a clinical-stage biopharmaceutical company translating unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs, today announced successful completion of the dose escalation segment of the Phase Ia/Ib clinical trial (NCT05826600) investigating OMX-0407, a first-in-class, spectrum-selective SIK (salt-inducible kinase) inhibitor, in patients with advanced solid tumors and opening of the expansion phase in kidney cancer and angiosarcoma.

Originally posted here:
iOmx Therapeutics Initiates Phase Ib with OMX-0407

Related Posts